Precision Neuroscience announced today that it received an investment from SCI Ventures, a specialist venture fund focused on paralysis.
SCI Ventures is backed by leading foundations in the U.S., UK and EU. Those include the Christopher & Dana Reeve Foundation, Wings for Life, Spinal Research, Promibilia and the Shepherd Center. Its backing supports Precision’s efforts with its brain-computer interface (BCI) technology.
Precision develops an ultra-thin cortical electrode array enabling BCI technology that aims to address paralysis. The Layer 7 thin-film brain-computer interface (BCI) features 1,024 electrodes embedded in a flexible film that conforms to the brain surface. It comes in at one-fifth the thickness of a human hair. This device aims to help users with severe paralysis operate digital devices, like computers and smartphones, using their thoughts.
The New York-based company won FDA clearance for Layer 7 in April. With the clearance, Layer 7 got the green light for commercial use with implantation durations of up to 30 days. The company said it was the first full regulatory clearance granted to a company developing a next-generation wireless BCI. It provided a leg up in the BCI market for Precision, which is going up against the likes of Neuralink, Synchron and others in the growing space.
Precision says SCI Ventures’ investment reflects its belief in the potential impact of the BCI field. The fund provides capital and deep networks of clinicians, regulatory experts, and patient advocates to the companies it backs. It aims to create an ecosystem that can help shorten the path from innovation to real-world use.
The funding adds to $102 million brought in through a Series C funding round late last year. That round brought the company to $155 million raised in total at the time.
Commentary from Precision Neuroscience and SCI Ventures leadership
Michael Mager, co-founder and CEO of Precision Neuroscience, said:
“The support of SCI Ventures, backed by the Reeve Foundation and other leaders in spinal cord injury advocacy, gives us added momentum at a pivotal time for brain–computer interfaces. People living with paralysis deserve solutions that are safe, effective, and practical to deliver at scale. With SCI Ventures as a partner, we’re one step closer to bringing this transformative technology to those who need it.”
Adrien Cohen, founding managing director of SCI Ventures, said:
“We’re excited to support Precision Neuroscience as part of a broader wave of innovators pushing brain–computer interface technologies toward real-world clinical impact. Precision stands out for its focus on less invasive solutions and its momentum in translating BCI from lab to bedside—a critical step in making these technologies truly accessible to people living with paralysis.”
